In both the European Union and United States, commissioners, regulators, and payers are making increasing evidential demands to show value in relation to the pricing and reimbursement of innovative medicines. Although the mechanisms differ, these demands stem from the same driver—the perceived need to control healthcare product budgets. Join our Washington, DC, and London lawyers and pricing and reimbursement experts for a one-hour webinar to discuss the issues and challenges arising from the growing need in both countries for producers to demonstrate value and share risk.
Topics will include:
CLE credit: CLE credit in CA (1.0 hour), FL, IL, NJ (via reciprocity), NY, PA, TX, and VA is currently pending approval.